Scarica l'app Stockscreener
19.46
2.91%
0.5601
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$18.90
Aprire:
$18.83
Volume 24 ore:
69,917
Relative Volume:
0.31
Capitalizzazione di mercato:
$334.47M
Reddito:
$116.88M
Utile/perdita netta:
$-25.09M
Rapporto P/E:
-139.00
EPS:
-0.14
Flusso di cassa netto:
$-20.74M
1 W Prestazione:
+0.46%
1M Prestazione:
+12.69%
6M Prestazione:
-11.87%
1 anno Prestazione:
+90.69%
Intervallo 1D:
$18.50
$19.75
Intervallo di 1 settimana:
$16.88
$25.42
Portata 52W:
$7.4843
$29.82
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Nome
Rigel Pharmaceuticals
Settore
Industria
Telefono
650-624-1100
Indirizzo
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Confronta RIGL con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RIGL
Rigel Pharmaceuticals
|
19.52 | 334.47M | 116.88M | -25.09M | -20.74M | -0.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.75 | 128.25B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
544.70 | 63.70B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
563.71 | 39.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
256.74 | 33.27B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
234.61 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-04-03 | Ripresa | Piper Sandler | Neutral |
| 2022-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-08 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-08 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-03-23 | Iniziato | B. Riley Securities | Neutral |
| 2020-11-09 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-15 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-09-26 | Ripresa | JP Morgan | Overweight |
| 2019-03-01 | Reiterato | Cantor Fitzgerald | Overweight |
| 2018-08-27 | Iniziato | Citigroup | Buy |
| 2018-05-02 | Reiterato | Cantor Fitzgerald | Overweight |
| 2017-12-21 | Ripresa | Piper Jaffray | Overweight |
| 2017-12-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-11-06 | Ripresa | H.C. Wainwright | Buy |
| 2017-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-31 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-30 | Reiterato | Piper Jaffray | Overweight |
| 2016-07-13 | Iniziato | H.C. Wainwright | Buy |
| 2016-06-13 | Iniziato | Piper Jaffray | Overweight |
| 2016-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2013-04-08 | Reiterato | Stifel | Buy |
| 2012-11-29 | Iniziato | UBS | Neutral |
| 2012-11-06 | Reiterato | Oppenheimer | Outperform |
| 2012-03-26 | Iniziato | Canaccord Genuity | Hold |
| 2010-12-10 | Downgrade | MP Advisors | Outperform → Market Perform |
Mostra tutto
Rigel Pharmaceuticals Borsa (RIGL) Ultime notizie
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance - MSN
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet - Yahoo Finance
Rigel Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Rigel Pharmaceuticals Reports Strong Growth and Strategic Advances - TipRanks
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) Price Target Raised by Cantor Fitzg - GuruFocus
Earnings call transcript: Rigel Pharmaceuticals sees stock surge after Q1 2025 earnings - Investing.com Nigeria
Earnings call transcript: Rigel Pharmaceuticals sees stock surge after Q1 2025 earnings By Investing.com - Investing.com South Africa
Rigel Pharma Jump 9.9% Premarket; Guides 'Positive' Net Income in 2025 After Swinging to Profit in Q1 - marketscreener.com
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Highlight - GuruFocus
Rigel Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Rigel: Q1 Earnings Snapshot - CTPost
Rigel Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals reports Q1 EPS 63c vs. 47c last year - TipRanks
Rigel Pharmaceuticals reaffirms FY25 revenue $200M-$210M, consensus $197.79M - TipRanks
Rigel Pharmaceuticals Inc Surpasses Q1 2025 Estimates with $0.64 EPS and $53.3 Million Revenue - GuruFocus
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
Rigel Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RIGL Projects Strong Financial Outlook for FY25 | RIGL Stock News - GuruFocus
Rigel Pharmaceuticals (RIGL) Surpasses Q1 Revenue Expectations | RIGL Stock News - GuruFocus
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update - Kilgore News Herald
Rigel Announces Conference Call and Webcast to Report First Quar - GuruFocus
Rigel Pharmaceuticals Sets Key Q1 2025 Earnings Date: How to Access Latest Biotech Results - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
(RIGL) Trading Report - news.stocktradersdaily.com
Rigel (RIGL) Upgraded to Buy: What Does It Mean for the Stock? - Nasdaq
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - marketscreener.com
Stocks That Fell to 3-Year Lows in the Week of Sept. 13 - GuruFocus
Where are the Opportunities in (RIGL) - news.stocktradersdaily.com
Rigel Pharmaceuticals: 3-Drug Company Reaches Profitability (RIGL) - Seeking Alpha
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
High Growth Tech Stocks in the US for April 2025 - simplywall.st
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Not Doing Enough For Some Investors As Its Shares Slump 26% - simplywall.st
Rigel settles patent litigation regarding its immune thrombocytopenia treatment - MSN
Rigel settles patent litigation over TAVALISSE treatment By Investing.com - Investing.com South Africa
Rigel Pharma stock rises on patent settlement (RIGL:NASDAQ) - Seeking Alpha
Rigel, Hetero Settle Patent Suit Over Platelet-Booster Tavalisse - Bloomberg Law News
Rigel climbs on blood disorder drug patent settlement - TradingView
Rigel settles patent litigation regarding its immune thrombocytopenia treatment (RIGL:NASDAQ) - Seeking Alpha
Rigel Pharma Settles Tavalisse Patent Litigation With Annora Pharma - Nasdaq
Rigel Pharmaceuticals Settles Patent Litigation Over Tavalisse - MarketScreener
Rigel Pharmaceuticals resolves patent litigation related to Tavalisse - TipRanks
Rigel Announces Settlement Agreement Resolving TAVALISSE® (Fostamatinib Disodium Hexahydrate) Patent Litigation - Marketscreener.com
Rigel settles patent litigation over TAVALISSE treatment - Investing.com
Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation - PR Newswire
Rigel Wins Patent Battle: TAVALISSE Exclusivity Protected Until 2032 in Major Settlement - Stock Titan
Rigel Pharmaceuticals Azioni (RIGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.73%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):